Continue to learn
Maxvax announced on October 31, 2025 the successful completion of its Series D financing round, raising over RMB 400 million. This round was jointly invested by IDG Capital, Shenzhen Capital Group (SCGC), and Ruipu Pharma. The funds will primarily support the clinical trials and commercialization preparation of Maxvax’s recombinant shingles (herpes zoster) vaccine, the Phase III clinical trial of its recombinant respiratory syncytial virus (RSV) vaccine, and preclinical research for multiple innovative vaccine candidates and international collaborations.
more >On January 23rd, Maxvax announced the successful enrollment and vaccination of all subjects in the Phase II clinical trial for its recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) at the Disease Control and Prevention Center in Liangyuan District, Shangqiu City, Henan Province. This marks the first domestic RSV vaccine to enter Phase II clinical trials in China.
more >On October 22, 2025, Maxvax Biotechnology Co., Ltd. (“Maxvax”) announced that its wholly owned subsidiary, Shanghai Maxvax Biotechnology Co., Ltd., has officially initiated the Phase III clinical trial for its Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell). The first group of participants has been successfully enrolled in Xianning, Hubei Province.
more >Maxvax's innovative novel adjuvant team has successfully published a landmark research article in one of the world’s most prestigious scientific journals, Angewandte Chemie International Edition (Impact Factor 16.1).
more >Recently, the registration application for the Adjuvanted Recombinant Herpes Zoster Vaccine (CHO Cell) independently developed by Shanghai Maxvax Biotechnology has been officially accepted by Chinese national regulatory authorities(Acceptance No. CXSS2500114).
more >Chengdu Maxvax Biotechnology LLC (Maxvax) announced the completion of a 200-million-yuan convertible bond financing on the day following New Year’s Day, with investment from Shenzhen Capital Group’s (SCGC) National New Materials Fund for Manufacturing Transformation and Upgrading.
more >
Maxvax announced on October 31, 2025 the successful completion of its Series D financing round, raising over RMB 400 million. This round was jointly invested by IDG Capital, Shenzhen Capital Group (SCGC), and Ruipu Pharma. The funds will primarily support the clinical trials and commercialization preparation of Maxvax’s recombinant shingles (herpes zoster) vaccine, the Phase III clinical trial of its recombinant respiratory syncytial virus (RSV) vaccine, and preclinical research for multiple innovative vaccine candidates and international collaborations.
more >
On October 22, 2025, Maxvax Biotechnology Co., Ltd. (“Maxvax”) announced that its wholly owned subsidiary, Shanghai Maxvax Biotechnology Co., Ltd., has officially initiated the Phase III clinical trial for its Recombinant Respiratory Syncytial Virus (RSV) Vaccine (CHO Cell). The first group of participants has been successfully enrolled in Xianning, Hubei Province.
more >
Recently, the registration application for the Adjuvanted Recombinant Herpes Zoster Vaccine (CHO Cell) independently developed by Shanghai Maxvax Biotechnology has been officially accepted by Chinese national regulatory authorities(Acceptance No. CXSS2500114).
more >
On January 23rd, Maxvax announced the successful enrollment and vaccination of all subjects in the Phase II clinical trial for its recombinant respiratory syncytial virus (RSV) vaccine (CHO cell) at the Disease Control and Prevention Center in Liangyuan District, Shangqiu City, Henan Province. This marks the first domestic RSV vaccine to enter Phase II clinical trials in China.
more >
Maxvax's innovative novel adjuvant team has successfully published a landmark research article in one of the world’s most prestigious scientific journals, Angewandte Chemie International Edition (Impact Factor 16.1).
more >
Chengdu Maxvax Biotechnology LLC (Maxvax) announced the completion of a 200-million-yuan convertible bond financing on the day following New Year’s Day, with investment from Shenzhen Capital Group’s (SCGC) National New Materials Fund for Manufacturing Transformation and Upgrading.
more >